Claims for Patent: 8,821,836

Summary for Patent: 8,821,836

Title:	SPARC binding peptides and uses thereof
Abstract:	The invention provides SPARC and Albumin binding peptides for the targeting of disease sites, such as tumors, with therapeutic and diagnostic agents. In particular, compositions comprising SPARC binding peptide-Antibody Fc domain fusion proteins and methods of their use are disclosed.
Inventor(s):	Trieu; Vuong (Agoura Hills, CA)
Assignee:	Abraxis BioScience, LLC (Los Angeles, CA)
Application Number:	13/896,973
Patent Claims:	1. A method of treating a mammal comprising administering to the mammal a therapeutically or diagnostically effective amount of a pharmaceutical composition comprising a therapeutic or diagnostic agent coupled to a SPARC-binding-peptide (SBP) and a pharmaceutically acceptable carrier, wherein the SBP consists of any one or more of SEQ ID NOS: 1-112 or 117. 2. The method of claim 1, wherein the therapeutic or diagnostic agent is a diagnostic agent selected from the group consisting of radioactive agents, MRI contrast agents, X-ray contrast agents, ultrasound contrast agents, and PET contrast agents. 3. The method of claim 1, wherein the pharmaceutical composition further comprises an albumin binding peptide (ABP) consisting of SEQ ID NO: 120. 4. The method of claim 1, wherein the mammal is a human patient. 5. The method of claim 1, wherein the SBP consists of SEQ ID NO: 1. 6. The method of claim 1, wherein the SBP consists of SEQ ID NO: 2. 7. The method of claim 1, wherein the therapeutic or diagnostic agent is a therapeutic agent selected from the group consisting of platinum compounds, antifolates, antimetabolites, antimitotics, DNA damaging agents, proapoptotics, differentiation inducing agents, antiangiogenic agents, antibiotics, tyrosine kinase inhibitors, kinase inhibitors, biologically active agents, biological molecules, hormones, peptides, antibodies, antibodies fragments and combinations thereof. 8. The method of claim 7, wherein the therapeutic agent is selected from the group consisting of radionuclides, adriamycin, ansamycin antibiotics, asparaginase, bleomycin, busulphan, cisplatin, carboplatin, carmustine, capecitabine, chlorambucil, cytarabine, cyclophosphamide, camptothecin, dacarbazine, dactinomycin, daunorubicin, dexrazoxane, docetaxel, doxorubicin, etoposide, epothilones, floxuridine, fludarabine, fluorouracil, gemcitabine, hydroxyurea, idarubicin, ifosfamide, irinotecan, lomustine, mechlorethamine, mercaptopurine, meplhalan, methotrexate, rapamycin (sirolimus), mitomycin, mitotane, mitoxantrone, nitrosurea, paclitaxel, pamidronate, pentostatin, plicamycin, procarbazine, rituximab, streptozocin, teniposide, thioguanine, thiotepa, taxanes, vinblastine, vincristine, vinorelbine, taxol, combretastatins, discodermolides, transplatinum, docetaxel, paclitaxel, taxanes, 5-fluorouracil, genistein, tTF, TNF, Smar1 derived p44 peptide, interferon, TRAIL, Smac, VHL, procaspase, caspase, and IL-2, a non-Fc domain antibody fragment, and combinations thereof. 9. The method of claim 7, wherein the therapeutic agent is an antibody fragment comprising a functional antibody Fc domain. 10. The method of claim 9, wherein the therapeutic agent is an antibody fragment which mediates one or more of complement activation, cell mediated cytotoxicity, inducing apoptosis, inducing cell death, and opsinization. 11. The method of claim 9, wherein the functional antibody Fc domain comprises SEQ ID NO: 118.

Details for Patent 8,821,836

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	01/10/1978		2028-12-05
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2028-12-05
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	02/19/2002		2028-12-05
Genentech, Inc.	RITUXAN HYCELA	rituximab and hyaluronidase human	Injection	761064	06/22/2017		2028-12-05